# OnCo record kras (target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/targets/kras/>
  a schema:BioChemEntity ;
  onco:kind "target" ;
  schema:identifier "kras" ;
  schema:name "KRAS"@en ;
  schema:description "KRAS is the most commonly mutated cancer gene, called 'undruggable' for 40 years until 2021."@en ;
  schema:url <https://onco.cc/targets/kras/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/KRAS>, <https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6407>, <https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000133703>, <https://www.uniprot.org/uniprotkb/P01116/entry>, <https://www.ncbi.nlm.nih.gov/gene/3845> ;
  owl:sameAs <http://www.wikidata.org/entity/Q20969980> ;
  schema:citation <https://en.wikipedia.org/wiki/KRAS> ;
  onco:tag "driver" ;
  schema:alternateName "KRAS" ;
  onco:targetClass "oncogene" ;
  onco:firstDescribed "1983"^^xsd:gYear ;
  onco:related <https://onco.cc/biomarkers/kras-g12d/>, <https://onco.cc/biomarkers/kras-g12c/>, <https://onco.cc/biomarkers/stk11-keap1-loss/>, <https://onco.cc/biomarkers/ras-wild-type/> ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/gallbladder/> ;
  onco:drugs <https://onco.cc/drugs/guardant360-cdx/>, <https://onco.cc/drugs/therascreen-cdx/>, <https://onco.cc/drugs/tempus-xt-cdx/>, <https://onco.cc/drugs/resolution-ctdx-first/>, <https://onco.cc/drugs/calderasib/>, <https://onco.cc/drugs/jdq443/>, <https://onco.cc/drugs/gfh375/>, <https://onco.cc/drugs/setidegrasib/>, <https://onco.cc/drugs/incb161734/>, <https://onco.cc/drugs/vs-7375/>, <https://onco.cc/drugs/jyp0015/> ;
  onco:companies <https://onco.cc/companies/adventris-pharmaceuticals/>, <https://onco.cc/companies/bridgebio-oncology-therapeutics/>, <https://onco.cc/companies/cogent-biosciences/>, <https://onco.cc/companies/erasca/>, <https://onco.cc/companies/imagene-ai/>, <https://onco.cc/companies/inivata/>, <https://onco.cc/companies/kumquat-biosciences/>, <https://onco.cc/companies/lucence/>, <https://onco.cc/companies/treeline-biosciences/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/pi3k-akt-mtor/>, <https://onco.cc/pathways/aml-signalling/>, <https://onco.cc/pathways/chemical-carcinogenesis-receptor-activation/>, <https://onco.cc/pathways/choline-metabolism-in-cancer/>, <https://onco.cc/pathways/cml-signalling/>, <https://onco.cc/pathways/colorectal-cancer-signalling/>, <https://onco.cc/pathways/endometrial-cancer-signalling/>, <https://onco.cc/pathways/gastric-cancer-signalling/>, <https://onco.cc/pathways/hepatocellular-carcinoma-signalling/>, <https://onco.cc/pathways/micrornas-in-cancer/>, <https://onco.cc/pathways/nsclc-signalling/>, <https://onco.cc/pathways/pancreatic-cancer-signalling/>, <https://onco.cc/pathways/renal-cell-carcinoma-signalling/>, <https://onco.cc/pathways/thyroid-cancer-signalling/> ;
  onco:terms <https://onco.cc/terms/kras-mutation-subtypes/>, <https://onco.cc/terms/wild-type/> ;
  onco:trials <https://onco.cc/trials/nct06385925/>, <https://onco.cc/trials/nct06667544/>, <https://onco.cc/trials/nct06243354/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-singhi-targeted-genome-profiling-3594-pdac-gastroenterology-2019/>, <https://onco.cc/key-papers/paper-philip-kras-wild-type-pancreatic-ccr-2022/>, <https://onco.cc/key-papers/paper-witkiewicz-pancreatic-exomes-utsw-nat-commun-2015/>, <https://onco.cc/key-papers/paper-tcga-pancreatic-integrated-characterisation-cancer-cell-2017/>, <https://onco.cc/key-papers/paper-bournet-kras-g12d-prognosis-pancreatic-ctg-2016/>, <https://onco.cc/key-papers/paper-qian-driver-genes-outcomes-resected-pancreatic-jama-oncol-2018/>, <https://onco.cc/key-papers/paper-daraxonrasib-pancreatic-n-engl-j-med-2026/>, <https://onco.cc/key-papers/paper-codebreak-100-sotorasib-kras-g12c-pancreatic-nejm-2023/>, <https://onco.cc/key-papers/paper-krystal-1-adagrasib-kras-g12c-solid-tumours-jco-2023/>, <https://onco.cc/key-papers/paper-heining-nrg1-fusions-kras-wild-type-pancreatic-cancer-discov-2018/>, <https://onco.cc/key-papers/paper-jones-nrg1-fusions-recurrent-actionable-kras-wild-type-pdac-ccr-2019/>, <https://onco.cc/key-papers/paper-karapetis-kras-cetuximab-colorectal-nejm-2008/>, <https://onco.cc/key-papers/paper-vogelstein-genetic-alterations-colorectal-tumor-development-nejm-1988/>, <https://onco.cc/key-papers/paper-loree-tumour-location-continuum-colorectal-ccr-2018/>, <https://onco.cc/key-papers/paper-sepulveda-molecular-biomarkers-colorectal-guideline-jco-2017/>, <https://onco.cc/key-papers/paper-schirripa-kras-g12c-metastatic-colorectal-clin-colorectal-cancer-2020/>, <https://onco.cc/key-papers/paper-codebreak-300-nejm-2023/>, <https://onco.cc/key-papers/paper-krystal-1-crc-yaeger-nejm-2023/>, <https://onco.cc/key-papers/paper-douillard-prime-panitumumab-ras-nejm-2013/>, <https://onco.cc/key-papers/paper-giraldo-gallbladder-msk-impact-ccr-2022/>, <https://onco.cc/key-papers/paper-li-gallbladder-exome-erbb-nat-genet-2014/>, <https://onco.cc/key-papers/paper-suryavanshi-indian-gallbladder-genomics-jco-go-2025/>, <https://onco.cc/key-papers/paper-javle-biliary-ngs-cancer-2016/>, <https://onco.cc/key-papers/paper-kris-lung-cancer-mutation-consortium-jama-2014/>, <https://onco.cc/key-papers/paper-alexandrov-tobacco-smoking-mutational-signatures-science-2016/> .